NOT

ONWARD® Medical Publishes Closing of Accelerated Bookbuild Offering and Public Offering in France

Retrieved on: 
Monday, March 25, 2024
Offerings, Private, Brussels Stock Exchange, Euronext, DSM-IV codes, NOT, Euronext Amsterdam, Movement, SCI, Security (finance)

EINDHOVEN, the Netherlands, March 25, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disorders, announces today the closing of its previously announced private placement with institutional investors, certain founders, certain members of management, and certain members of the Board of Directors (the “Private Placement”) and of its separate public offering via the PrimaryBid platform with retail investors in France (the “Public Offer” and together with the Private Placement the “Offerings”).  The gross proceeds from the Offerings amount to €20 million. 

Key Points: 
  • OTHER RESTRICTIONS ARE APPLICABLE.
  • PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
  • As of today, the new shares issued pursuant to the Offerings are admitted to listing and trading on Euronext Brussels and Euronext Amsterdam.
  • This press release does not constitute, contain, or form part of an offering of securities in any jurisdiction.

ReconAfrica Announces Upsize of Bought-Deal Public Offering to C$15 Million

Retrieved on: 
Friday, March 22, 2024
Indian stock exchange, TSX Venture Exchange, Offering, Warrant, Sale, Exercise, NOT, Person, Security (finance)

VANCOUVER, British Columbia, March 22, 2024 (GLOBE NEWSWIRE) -- Reconnaissance Energy Africa Ltd. (the “Company” or “ReconAfrica”) (TSXV: RECO) (OTCQX: RECAF) (Frankfurt : 0XD) is pleased to announce that it has entered into an amended agreement with Research Capital Corporation as the sole bookrunner and lead underwriter, on behalf of a syndicate of underwriters (collectively, the “Underwriters”) to increase the size of its previously announced bought-deal public offering, pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 16,666,700 units of the Company (the “Units”) at a price of C$0.90 per Unit for aggregate gross proceeds to the Company of C$15,000,030 (the "Offering").

Key Points: 
  • Each Unit shall be comprised of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant").
  • Each Warrant shall entitle the holder thereof to purchase one Common Share (a “Warrant Share”) at an exercise price of C$1.15 at any time up to 24 months from the closing of the Offering.
  • Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.
  • The net proceeds from the Offering will be used for exploration and development activities, working capital and other general corporate purposes.

ReconAfrica Announces C$10 Million Bought-Deal Public Offering

Retrieved on: 
Friday, March 22, 2024
Indian stock exchange, TSX Venture Exchange, Offering, Warrant, Sale, Exercise, NOT, Person, Security (finance)

VANCOUVER, British Columbia, March 21, 2024 (GLOBE NEWSWIRE) -- Reconnaissance Energy Africa Ltd. (the “Company” or “ReconAfrica”) (TSXV: RECO) (OTCQX: RECAF) ( Frankfurt : 0XD) is pleased to announce that it has entered into an agreement with Research Capital Corporation as the sole bookrunner and lead underwriter, on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 11,112,000 units of the Company (the “Units”) at a price of C$0.90 per Unit for aggregate gross proceeds to the Company of C$10,000,800 (the "Offering").

Key Points: 
  • Each Unit shall be comprised of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant").
  • Each Warrant shall entitle the holder thereof to purchase one Common Share (a “Warrant Share”) at an exercise price of C$1.15 at any time up to 24 months from the closing of the Offering.
  • The net proceeds from the Offering will be used for exploration and development activities, working capital and other general corporate purposes.
  • Copies of the base shelf prospectus and any supplement thereto to be filed in connection with the Offering, are and will be available under the Company’s profile on SEDAR+ at www.sedarplus.ca .

Alaris Equity Partners Income Trust Declares Q1 Distribution

Retrieved on: 
Thursday, March 21, 2024
Trustee, Distribution, NOT, TSX

CALGARY, Alberta, March 21, 2024 (GLOBE NEWSWIRE) -- Alaris Equity Partners Income Trust (“Alaris” or the “Trust”) (TSX: AD.UN) announces that the Board of Trustees of the Trust (the “Board”) has declared a trust distribution (“Distribution”) of $0.34 per trust unit for the first quarter of 2024, representing $1.36 per unit on an annualized basis. The Distribution is payable on April 15, 2024 to unitholders of record on March 29, 2024.

Key Points: 
  • NOT FOR DISTRIBUTION IN THE UNITED STATES.
  • FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.
  • CALGARY, Alberta, March 21, 2024 (GLOBE NEWSWIRE) -- Alaris Equity Partners Income Trust (“Alaris” or the “Trust”) (TSX: AD.UN) announces that the Board of Trustees of the Trust (the “Board”) has declared a trust distribution (“Distribution”) of $0.34 per trust unit for the first quarter of 2024, representing $1.36 per unit on an annualized basis.
  • The Distribution is payable on April 15, 2024 to unitholders of record on March 29, 2024.

ONWARD® Medical Publishes Prospectus for Listing of New Shares

Retrieved on: 
Thursday, March 21, 2024
EUR, Offerings, AFM, Euronext, Prospectus, DSM-IV codes, Market, NOT, Movement, SCI

EINDHOVEN, the Netherlands, March 21, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disorders, announces today that it has published a prospectus for the admission to listing of 4,444,444 ordinary shares in the Company’s share capital, with a nominal value of EUR 0.12 each, issued through a private placement with institutional investors, certain founders and certain members of management, and certain members of the Board of Directors (the “Private Placement”) and in a separate public offering via the PrimaryBid platform with retail investors in France (the “Public Offer”), for which pricing and allocation have occurred prior to trading on March 21, 2024 (the “Offerings”). In connection with the listing of the shares placed in the Offerings, a listing prospectus was published today. The prospectus was approved by the Netherlands Authority for the Financial Markets (AFM) on March 21, 2024 and can be downloaded via ir.onwd.com/shareholder-information.

Key Points: 
  • PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
  • In connection with the listing of the shares placed in the Offerings, a listing prospectus was published today.
  • The prospectus was approved by the Netherlands Authority for the Financial Markets (AFM) on March 21, 2024 and can be downloaded via ir.onwd.com/shareholder-information .
  • This press release does not constitute, contain, or form part of an offering of securities in any jurisdiction.

ONWARD® Medical Successfully Raises €20 Million in a Capital Increase by Way of an Accelerated Bookbuild Offering and by Way of a Public Offering in France

Retrieved on: 
Thursday, March 21, 2024
Offerings, Public, Private, Brussels Stock Exchange, KBC, Euronext, DSM-IV codes, CSO, Euronext Amsterdam, NOT, SCI, Movement, Hand, Security (finance)

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Key Points: 
  • PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
  • “We are delighted to announce the successful capital raise of €20 million, including a fully subscribed upsize option despite challenging market conditions,” said Dave Marver, CEO of ONWARD Medical.
  • Existing shareholders participated in the deal with an aggregate of 333,333 shares and 333,333 shares respectively allocated to INKEF Capital and EQT Life Sciences.
  • Following the Offerings, INKEF Capital and EQT Life Sciences will respectively hold 11.5% and 11.2% of the Company’s share capital.

Helios Fairfax Partners Appoints Katherine Cunningham to its Board of Directors

Retrieved on: 
Wednesday, March 20, 2024
Financial management, Sun Life Financial, Financial services, Communication, Commerce, TSX, NOT, CPA

TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- Helios Fairfax Partners Corporation (TSX: HFPC.U) (“HFP”) announces that it has appointed Katherine Cunningham as an independent director.

Key Points: 
  • NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
    TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- Helios Fairfax Partners Corporation (TSX: HFPC.U) (“HFP”) announces that it has appointed Katherine Cunningham as an independent director.
  • Katherine Cunningham is the Chief Financial Officer at The Globe and Mail Inc., Canada’s national newspaper, where she is responsible for strategy, corporate development and all aspects of financial management.
  • Until 2019, she was a Senior Vice President at Sun Life Financial Inc., holding SVP Finance, Chief Financial Officer Canada, and Chief Auditor roles.
  • Prior to joining Sun Life in 2014, Ms. Cunningham was an Audit Partner at KPMG Canada LLP in the Communications and Media and, later, Financial Services industries.

Urbana Corporation Has Filed Audited 2023 Annual Financial Statements

Retrieved on: 
Tuesday, March 19, 2024
Financial statement, Analysis, TSX, WIRE, NOT

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Urbana Corporation (TSX & CSE: URB & URB.A)

Key Points: 
  • /NOT FOR DISTRIBUTION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE U.S./
    TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Urbana Corporation (TSX & CSE: URB & URB.A)
    Urbana Corporation announces today that it has filed its audited Financial Statements and Management’s Discussion and Analysis for the year ended December 31, 2023 with the applicable Canadian securities regulators.

Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million

Retrieved on: 
Friday, March 15, 2024
Indian stock exchange, Bookrunner, Exercise, Offering, Research, Sale, Bank statement, Prospectus, TSX, Eupraxia, NOT

VICTORIA, British Columbia, March 15, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has closed its previously announced overnight marketed public offering (the “Offering”) of common shares of the Company (the “Shares”). Pursuant to the Offering, Eupraxia issued 8,260,435 Shares at a price of C$4.10 per Share for gross proceeds of C$33,867,784, which includes the issuance of 943,435 Shares upon exercise of the over-allotment option.

Key Points: 
  • Pursuant to the Offering, Eupraxia issued 8,260,435 Shares at a price of C$4.10 per Share for gross proceeds of C$33,867,784, which includes the issuance of 943,435 Shares upon exercise of the over-allotment option.
  • Eupraxia expects to use the net proceeds of the Offering, together with its existing cash and cash equivalents, primarily to fund research and development activities, general and administrative expenses, a milestone payment, working capital needs and other general corporate purposes.
  • The Common Shares were offered pursuant to a final prospectus supplement dated March 12, 2024 to the Company’s short form base shelf prospectus dated February 5, 2024.
  • Raymond James Ltd. acted as sole underwriter and bookrunner for the Offering.

Helios Fairfax Partners to Host Investor Presentation on Wednesday, April 10, 2024 at 2:30 pm ET and Annual General Meeting of Shareholders on Tuesday, May 14, 2024 at 11:00 am ET

Retrieved on: 
Friday, March 15, 2024
Annual, NOT, TSX, The Ritz-Carlton Hotel Company, HFP

TORONTO, March 15, 2024 (GLOBE NEWSWIRE) -- Helios Fairfax Partners Corporation (TSX: HFPC.U) (“HFP”) today announced it will host an Investor Presentation on Wednesday, April 10, 2024 at 2:30 pm ET in-person at the Ritz-Carlton Hotel, 181 Wellington Street West, Toronto, Ontario, and virtually via live webcast. To register in advance and join the Investor Presentation webcast visit: https://hfpinvestorpresentation2024.can.chime.live/. On the day of the meeting please connect approximately 15 minutes prior to the beginning of the webcast to ensure participation.

Key Points: 
  • To register in advance and join the Investor Presentation webcast visit: https://hfpinvestorpresentation2024.can.chime.live/ .
  • On the day of the meeting please connect approximately 15 minutes prior to the beginning of the webcast to ensure participation.
  • HFP will also host its Annual General Meeting of Shareholders on Tuesday, May 14, 2024 at 11:00 am ET as a virtual meeting.
  • On the day of the meeting please connect approximately 15 minutes prior to the beginning of the webcast to ensure participation.